In the Netherlands, the Dutch National Institute for Public Health and the Environment (RIVM) has published a study that makes several recommendations for companies looking to register biobased substances under European Union’s Registration, Evaluation, Authorisation and Restriction of Chemicals legislation.
Many of the questions biobased companies have about REACH—and are addressed in the report—is whether or not they qualify for exemptions that may lessen the registration burden, the study notes. REACH offers benefits for producers that provide biobased alternatives to substances of very high concern. “REACH may actually be an opportunity rather than the administrative hurdle it is often perceived to be,” RIVM says.